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Abstract
In this paper, we review the management of neonatal opioid withdrawal syndrome
(NOWS) and clinical pharmacology of primary treatment agents in NOWS, including
morphine, methadone, buprenorphine, clonidine, and phenobarbital. Pharmacologic
treatment strategies in NOWS have been mostly empirical, and heterogeneity in dosing regimens adds to the difficulty of extrapolating study results to broader patient
populations. As population pharmacokinetics (PKs) of pharmacologic agents in
NOWS become more well-defined and knowledge of patient-specific factors affecting treatment outcomes continue to accumulate, PK/pharmacodynamic modeling and
simulation will be powerful tools to aid the design of optimal dosing regimens at the
patient level. Although there is an increasing number of clinical trials on the comparative efficacy of treatment agents in NOWS, here, we also draw attention to the importance of optimizing the dosing regimen, which can be arguably equally important at
identifying the optimal treatment agent.

I N T RO D U C T ION
Neonatal opioid withdrawal syndrome (NOWS), traditionally referred to as neonatal abstinence syndrome (NAS), is
the withdrawal syndrome that occurs in neonates who are
exposed to opioids in utero.1 The sharp increase in NOWS
incidences from 1.2 to 8.8 for every 1000 hospital births from
2000 to 2016 can be ascribed to a rise in maternal opioid use.1
NOWS is characterized by hyperactivity of the central nervous system (CNS) and dysregulation of autonomic nervous
system.2 Neonates with NOWS exhibit symptoms that range
from tremors, poor feeding, irritability, to increased muscle
tone, fever, and seizures,3 and these newborns are more likely
to have low birth weight and respiratory complications than
other newborns.4
The significant growth in the incidence of NOWS in recent
years corresponded to a significant upward trend in associated
national healthcare expenditures. Hospital costs covered by

Medicaid increased substantially from $65.4 million in 2004
to $462 million in 2014.5 There is a need to improve the effectiveness and efficiency of NOWS treatment, decrease the
length of hospitalization of these newborns, and reduce associated healthcare expenditures. Previous retrospective studies
showed that use of standard treatment protocols could reduce
treatment and hospitalization duration.6 However, there is a
lack of consensus on NOWS treatment protocols on pharmacotherapy procedures, and there exists significant variability in treatment outcomes due to patient-specific factors and
site-to-site variations in treatment duration, length of stay,
and hospital charges.7 In-depth understanding of the clinical
pharmacology of treatment agents will greatly enhance our
ability to optimize therapy in infants with NOWS, as it is
essential for formulating evidence-based treatment protocols.
To this end, we first provide an overview of NOWS management, then delve into the details of clinical pharmacology for primary treatment agents and summarize available
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pharmacokinetic (PK) studies in the neonates. Finally, we
will discuss the current progress and future research needed
for dosing regimen optimization integrating PK/pharmacodynamic (PD) evidence. Although NOWS has been the focus
of a number of recent review papers, our review paper aims
to emphasize on current experiences and future perspectives
of dosing regimen optimization in NOWS.

OV ERV IE W OF T H E MA NAGE M ENT
O F NOWS
The diagnosis and treatment of NAS in clinical practice is
typically guided by scoring systems that evaluate the withdrawal symptoms, but there is no consensus on a single scoring tool. The most widely used tool is the Finnegan Neonatal
Abstinence Scoring Tool; the modified Finnegan Score
from the MOTHER trial is also commonly used.1 It is also
worth mentioning that a new scoring tool named Eat, Sleep,
Console has been introduced recently with potential advantages (i.e., reduced use of pharmacologic treatment and hospital stay) over the traditional scoring tools.8 Overall, these
scoring tools support the decision to start pharmacologic intervention in patients who have severe symptoms and/or fail
to respond to nonpharmacologic management, and to guide
dosing escalation/de-escalation in these patients.9
Nonpharmacologic treatment is indicated in all infants as
the foundation of care and should be continued throughout
hospitalization whether or not the infants receive pharmacologic treatment.1 Examples of nonpharmacologic interventions include breastfeeding, decreasing environmental stimuli,
responding early to signals, and giving small and frequent
feedings.1,3 Use of pharmacotherapy is indicated in severe
NOWS in addition to nonpharmacologic interventions to relieve withdrawal symptoms and minimize complications from
withdrawal.1 However, it must be noted that the clearly proven
benefit of pharmacologic treatment is limited to short-term
symptomatic relief.3 Unnecessary pharmacologic intervention
may lead to prolonged exposure to drugs and hospital stay.3
A study on the incidence of NAS in 299 neonatal intensive care units in the United States reported that the most
commonly prescribed medications, morphine, was used in
72% of the infants in 2013, compared with phenobarbital,
methadone, and clonidine in 20%, 15%, and 9% of the infants,
respectively.10 These findings were in line with the American
Academy of Pediatrics (AAP) Guidelines on NOWS, which
recommended using an opioid as a first-line treatment agent.1
The guidelines recognize emerging evidence on the potential advantage of longer-acting opioids (e.g., methadone and
buprenorphine) over morphine in terms of duration of treatment/hospital stay.1 Additionally, on the use of adjunctive
or secondary treatment agent, the guidelines favor clonidine
over the more commonly used phenobarbital due to potential
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safety concerns of phenobarbital, although there is insufficient evidence on the comparative efficacy of the two agents.1
A recent systematic review, including 18 randomized
clinical trials of pharmacological therapy (N = 1072), found
that sublingual buprenorphine performed the best in terms
of length of treatment, followed by clonidine, dilute tincture
of opium (DTO), methadone, morphine, and phenobarbital
monotherapy.11 However, the analysis results were sensitive
to imprecision due to insufficiently powered comparisons.11
The authors commented that although the shorter lengths of
treatment associated with buprenorphine might be due to its
prolonged half-life and receptor activity, it was unclear how
much of such observed benefits was in fact due to the optimization of treatment protocol and weaning schedule in the
buprenorphine trials.11 When comparing different treatment
agents, safety profiles should also be taken into consideration. Clinically, the commonly used opioids and clonidine
have favorable safety profiles with inpatient use; phenobarbital appears clinically safe, but its effect on neurodevelopment
is a potential concern.1 Nevertheless, standardized protocols
should be used to minimize opioid exposure,1 given the concerns raised by experimental data on the long-term neurodevelopmental effect of opioids.12 Another potential concern
may lie with drug formulation. It is still unclear what level
of ethanol exposure is considered safe in neonates, but it is
recommended that medications containing ethanol should be
used with caution in neonates.13 The AAP established an arbitrary ethanol concentration limit of 0.25 g/L following a
single dose.14 However, ethanol concentrations ranging from
0.01 to 1 g/L have been related to CNS adverse effects in
children in the literature.15 In terms of specific drug formulations, preservative-free morphine is commercially available,
but the commercially available methadone contains 15% ethanol. Preservative-free methadone has been compounded for
use in clinical trials.16 On the other hand, buprenorphine used
in NOWS trials contains a high amount of alcohol, with one
reported formulation containing 30% of ethanol.17
Although there is an increasing number of clinical trials
on the comparative efficacy of treatment agents in NOWS,
here, we also draw attention to the importance of optimizing
the dosing regimen, which can be arguably equally important at identifying the optimal treatment agent. Oftentimes,
variations in starting doses, escalation/weaning schemes, and
use of adjunctive therapy and nonpharmacological therapy
may limit the generalizability of comparative efficacy study
results to broader patient populations. Although most treatment protocols involve rapid uptitration of an opioid and
subsequent weaning at typically 10% increments, treatment
approaches differ significantly across institutions and there is
no consensus on the standard of care.18 Therefore, in addition
to studying comparative efficacy, optimization of dosing regimens should also be a priority for future research. In-depth
understanding of clinical pharmacology for individual agents
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will be key to therapy optimization, as it serves as the basis
for the use of population PK/PD modeling and simulation to
inform the design of treatment strategies.

DE V ELO P M E N TA L
PH A R M ACO KIN E T IC S IN
NE O NAT E S
Physical and biological differences in children and adults
lead to their differences in drug exposure (PKs) and/or exposure response (PDs, with PKs referring to the processes
of drug disposition in the body (i.e., absorption, distribution,
metabolism, and excretion [ADME]), and PD referring to the
body’s physiological and biological response to the therapeutic agent.19 Developmental changes in childhood comprise
maturation of enzyme pathways (related to PKs), as well as
expression and activity of receptors and proteins (related to
PDs).19 Such maturation processes are often nonlinear and
do not correlate with body weight alone, and therefore linear
extrapolations from adult dosing to pediatric dosing based on
body weight (i.e., the linear per kilogram model) is often an
oversimplification and may lead to under-or overdosing.19
Because pediatric studies often involve sparse sampling and
unbalanced design, a population approach with nonlinear
mixed effect modeling is the preferred tool to study PK and
PD parameters. The power of the population approach lies in
its ability to use all available individual data to estimate population mean of the parameters, as well as estimating the inter-and within-individual variability.20 The resulting models,
once validated, can be used to derive rational dosing schemes
that are predicted to be safe and effective, which in turn can
be challenged and tested in prospective clinical trials.19
Using the population approach, the effect of developmental changes in children can be investigated mainly by testing
size (body weight) and/or age as predictors (covariates) of
PK/PD variability.19 Size can be incorporated in the model
either a priori by allometric scaling (fixed allometric model)
or as a covariate as any other (systematic covariate model).19
Allometric scaling relations have been used to describe
how biological variables change dependent on body mass.
The use of 3/4 as the scaling exponent for metabolic rates
is well supported by theoretical and experimental evidence,
and therefore it can be used as the power parameter for drug
clearance (CL).21 Volume of distribution (V) has been found
to be directly proportional to body weight, so one can be used
as the scaling exponent for volume terms.21 Although the use
of allometry can help explain the influence of body size, it
cannot fully explain the maturation trajectory of metabolizing enzymes, receptors, and transporters, which contributes
to considerable variability observed in neonates.22 For example, the dominant CYP3A enzyme in the fetus is CYP3A7
and its level gradually decreases after birth as expression of
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CYP3A4 increases.23 In fact, the majority of drug metabolizing enzymes are expressed at low levels before birth, and
their expression levels mature within a few weeks in the case
of CYP2D6, or within 1–2 years after birth in the case of
CYP1A2 and CYP3A4.23 Renal function and liver blood
flow also mature as a function of age.19 Additionally, body
composition evolves continuously in childhood, which can
affect the volume of distribution of drugs. Neonates have
much higher percentage of total body water (80%–90% of
body weight) than adults (55%–60% of body weight). As a
result, for hydrophilic drugs, a larger volume of distribution
is observed in neonates than in adults.19 Therefore, influence
of age should be explored next as a covariate, and postmenstrual age (PMA), gestational age (GA), and postnatal age
(PNA) can all be tested as age descriptors.
As an example, Holford et al.24 proposed a “standard
approach” to model PK parameters in children following
Equations 1and 2:

CL = CLstd ×

(

WT
WTstd

)3∕4

V = Vstd ×

(

×

PMAHILL
(1)
PMAHILL + TMHILL
50

WT
WTstd

)

(2)

where WTstd is usually set to 70 kg; CLstd and Vstd stand for
clearance and volume in a reference adult with weight of WTstd;
PMA refers to postmenstrual age, TM50 refers to the maturation
half-life, and HILL stands for the Hill coefficient in a sigmoidal
maximum effect (Emax) model. The authors proposed that PNA
was not as a good predictor as PMA, because most maturation
processes start in utero.25 Maturation of clearance may also be
described with other functions, such as linear, exponential, and
asymptotic exponential models, the advantages and disadvantages of which are discussed elsewhere.21 Changes in volume of
distribution in relation to age can occur due to changes in body
composition, and such changes may be described with similar
functions as those used for clearance.21
Last, one needs to be cautious when interpreting the results from models incorporating both body weight and age-
dependent maturation. We could use such models to predict
when the parameter (e.g., CL and V) in neonates reach certain percentage of the adult value, with body weight already
taken into account using the weight function in the model.
For example, it was reported that the glomerular filtration
rate (GFR) in ml/min/70 kg is 35% of the adult value in neonates and reaches adult value at around the age of 1 year.26
This should not be interpreted as the actual GFR value in
children older than 1 year of age is the same as that in adults.
Rather, based on this model, the actual GFR value in children
aged over 1 year continues to grow, but this growth can be
explained by weight alone.
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|

  

PH A R M ACO LOGY A N D
PH A R M ACO KIN E T IC S OF F IR ST-
LI N E AG E N TS IN NOWS
Morphine
Pharmacology
Morphine is a μ-opioid agonist used for treating moderate-to-
severe pain. Its binding to μ-opioid receptors is responsible
for its therapeutic effect of analgesia, sedation, euphoria, and
respiratory suppression.27 Glucuronidation of hydroxyl groups
on 3-and 6-positions mainly by UDP-glucuronosyltransferases
2B7 produces morphine-3-glucuronide (M3G) and morphine-
6-glucoronide (M6G).28 Multiple studies have shown that
M6G is a strong μ-opioid agonist with analgesic properties that
contribute significantly to analgesic effect of morphine, and it
appears to have less respiratory depressant effects than morphine.29 In contrast to M6G, M3G has very low binding affinity
for μ-opioid receptors with no analgesic properties.30

PK in adults
Morphine undergoes extensive hepatic first-pass metabolism,
leading to relatively low bioavailability (~20%–30%).31 Time
to the maximum plasma concentration (Tmax) is ~ 1 h after oral
dosing.32 Its distribution has been modeled by one, two, and
three compartments in reported literature, and studies that had
the longest and most frequent sample collection tend to favor
three-compartment models.31 Reported steady-
state volume
of distribution ranges from 1 to 4 L/kg.33 Ninety percent of
the dose is metabolized, with an estimate of 45%–55% of the
dose converted to M3G and 10%–15% to M6G, and the rest
to minor metabolites, including normorphine, morphine-3,6-
diglucuronide, morphine-3-ethereal sulfate, normorphine-6-
glucuronide, normorphine-3-glucuronide, and codeine.34 The
route of administration has been reported to affect the M3G/
M6G to morphine plasma area under the concentration-time
curve (AUC) ratios, indicating these glucuronide metabolites
are formed from both first-pass effect and systemic clearance.35
Estimated total clearance ranges from 75 to 118 L/h,31 which
supports that morphine has a high hepatic extraction ratio.
Estimated elimination half-life ranges from 1.4 to 2.7 h.35,36
M3G and M6G are both eliminated by the kidneys, and the exposure to both metabolites increases in renal impairment.37

PKs in neonates
Compared with adults, morphine CL is lower in neonates due to immature glucuronidation capacity, but it is
well-established that term neonates are able to metabolize
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morphine to M3G and M6G.38 In term neonates, renal excretion of unchanged morphine accounts for a higher proportion of total body clearance (~19%), compared with adults
(~10%).38
Pediatric studies have found that morphine CL (when
expressed on a linear per kg basis) increases with age and
reaches adult values between 1 and 6 months of age.38–40 A
meta-analysis by Kart et al.38 on estimated PK parameter values in the pediatric population reported that the mean volume of distribution was 2.8 L/kg in neonates and children
regardless of the age, which is in the range of the adult value
on a linear per kg basis. Pooled estimates of half-life were
9.0 h and 6.5 h in preterm neonates and term neonates aged
0–57 days, which were significantly longer than adult adults
(~1.4 to 2.7 h).38 Correspondingly, pooled estimates of clearance ranged from 2.2 to 8.1 ml/min/kg (0.13–0.49 L/h/kg)
in preterm neonates and term neonates, respectively.38 It is
apparent that in neonates, weight-normalized morphine CL
increases with gestational and postnatal age, although up to
a seven-fold interindividual variation in clearance has been
reported in neonate studies.38
A number of population PK models for morphine have
been proposed in the pediatric population that included neonates. However, they differed in terms of the number of
compartments for the parent compound and/or the glucuronide metabolites, parameterization of allometric equations,
how/which age descriptors were incorporated into clearance
and/or volume, and what maturation functions were used.
Comparative performance of these models and other published pediatric PK models in describing pediatric morphine
PK observations has been studied elsewhere with divergent
conclusions.41–43
Liu et al.44 reported a morphine population PK model
in NOWS based on 88 blood samples collected from 34
neonates who were given DTO orally (containing 0.04 mg
morphine per ml). Prior to this report, there had only been
studies of morphine PKs following intravenous administration in pediatric patients. In the development of the population PK model, the authors used data from adult patients who
received intravenous morphine with rich sampling scheme.45
The authors started with a three-compartment model used in
the adult study, followed by addition of allometric scaling
to PK parameters. Maturation of clearance based on PMA
using a sigmoidal maturation model and maturation of central volume based on PNA using an exponential model were
also used. Last, the model included the addition of first-
order absorption rate constant and bioavailability parameters
(Table 1).44 Standardized clearance estimate (75.3 L/h/70 kg)
was in the range of previously reported adult values. The authors confirmed the findings by Holford et al.42 that time to
reach 50% of adult value of clearance was 58.3 weeks PMA,
and that of central volume was 9.65 weeks PNA (standardized to a 70 kg person).44

  

PHARMACOLOGY OF NOWS TREATMENTS

TABLE 1
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Summary of published population PK models for pharmacologic agents in neonatal opioid withdrawal syndrome

References

Agent

Number of samples/subjects

Parameterizationa

Liu et al.44,46

Morphine

Liu et al.44: 88 samples from 34 neonates.
Sampling: 2–3 samples per subject at
random

( )0.75
PMAHillCL
CL = CLstd ×( Wt
) ( × PMAHillCL + CLmatHillCL
)
70
50 ln ( 2 )
V1 = V1std × (Wt
× 1 + 𝛽vol × e − PNA × Tvol
70 )

46

Liu et al. : 348 samples from 81 neonates
from three studies.
Sampling:
-JHU-Morphine trial: up to 4 samples per
subject at random
-BBORN trial: pre-defined sparse
sampling (peak, trough, after dose
cessation), 4–16 samples per subject
-JHU-DTO trial: 2–3 samples per subject
at random (Liu et al.44)
Wiles et al.60

Methadone

71 samples from 20 neonates.
Sampling: 3 samples related to a single
dose and 1 optional sample per subject

van Donge
et al.61

Methadone

121 samples from 31 neonates.
Sampling: all taken after a single oral dose

Ng et al.73

Buprenorphine

209 samples from 24 neonates and 94
samples from 5 adults.
Sampling: trough or peak

Moore
et al.74

Q2 = Q2std ×( Wt
70)
V2 = V2std × (Wt
70 )
Q3 = Q3std ×( Wt
70)
V3 = V3std × Wt
70

0.75

( )0.75
Wt
CL∕F = CL∕Fstd
( × ) 70
V∕F = V∕Fstd × Wt
70

V∕F = V∕Ftypical ×
(

(

GA
)
GAmedian
GA
GAmedian

CL∕F = CL∕Ftypical(×
CL∕F = CL∕Fstd ×

265 samples from 28 neonates.
Sampling: at least one peak within 24
hours; peak and trough surrounding a
single dose or as a mid-dose
Interval timepoint

0.75

Emax × PNASLP
KMSLP + PNASLP

(

)

Wt
V2∕F = V2∕Fstd ×
( 70
)0.75
Q∕F = Q∕Fstd × Wt
(
70

V3∕F = V3∕Fstd × BASE +

)𝜃GA_CL

) ( )0.75
+ ( 1 − Emax ) × ( 1 − e − TF × PNA ) × Wt
70

(1 - BASE) × PNASLP1
KMSLP1
+ PNASLP1
V3

)

Mizuno
et al.75

Buprenorphine

52 samples from 19 neonates.
Sampling: three samples collected around
the second dose

No covariates included on PK parameters

Xie et al.92

Clonidine

102 samples from 36 neonates.
Sampling: 2–3 samples per subject at
random

( )0.75
Wt
×
CL∕F = CL∕Fstd
( × ) 70
Wt
V∕F = V∕Fstd × 70

×

(

Wt
70

)

PNAHILL
PNAHILL + THILL
50

Abbreviations: CL, clearance; CL/F, total apparent clearance; Emax, maximum effect; GA, gestational age; PK, pharmacokinetic; PMA, postmenstrual age; PNA,
postnatal age.
a

Parameters with standard subscript: parameter value standardized to 70 kg adults.

In a more recent publication by Liu et al., the authors expanded their original DTO population PK model by incorporating data from two additional clinical trials in neonates
treated with enteral morphine for in utero-acquired and intensive care unit-acquired NOWS (Table 1).46 With this expanded dataset (a total of 81 neonates), a PNA-dependent
model bias was identified; as a result, in the updated model,
PNA effect was added to both clearance and bioavailability terms to account for PNA-dependent morphine CL.46 In
contrast to the bioavailability estimate in the original DTO
population PK model (48.5%), with the updated model, bioavailability is predicted to be high shortly after birth and
decrease to 20% in patients older than 7 days PNA, a value
similar to reported morphine bioavailability in adults.46
Although enzyme maturation is typically related to PMA,
the authors hypothesized that their findings of PNA effect

on morphine CL after adjustment of body weight and PMA,
may be explained by PNA-dependent formation of uridine diphosphate glucuronic acid that leads to PNA-dependent glucuronidation activity during the first week of life.46 However,
further experimental and clinical data will be needed to substantiate this hypothesis.
A summary of neonatal and adult PK parameters and
morphine elimination is presented in Figure 1.

Methadone
Pharmacology
Methadone is synthetic μ-opioid agonist widely used for
treatment of opioid addiction and chronic pain.47 Although
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F I G U R E 1 Comparative
pharmacokinetic parameters and elimination
of morphine in neonates/infants and
adults. *Clearance increases with age (0–
57 days).38 NE, not estimated; t1/2, terminal
half-life

methadone is a full μ-opioid receptor agonist, it has lower
abuse potential than morphine, likely due to its long duration
of effect in suppressing withdrawal; it is thus used for addiction treatment.36 Methadone is marketed as a racemic mixture. Compared with (S)-methadone, (R)-methadone binds to
μ and δ opioid receptors with 10 times higher affinity and
has up to 50 times of analgesic activity.48 (S)-methadone
is generally considered to be ineffective,49 but there is also
evidence that it has antagonist activity at the N-methyl-d-
aspartate (NMDA) receptor, and it may be able to decrease
the development of opioid tolerance through NMDA receptor antagonism.50

be attributed to variation in urinary pH and enzyme activity, and renal clearance of methadone only becomes quantitatively important when urine pH is less than 6.55 On the
other hand, one study reported the AUC ratio of methadone
over EDDP in the first 24 h after oral dosing ranged from
5.9 to 44.6, indicating large interindividual variations due
to different metabolic activity.56 Such variability in methadone disposition could be partially explained by variations in
CYP2B6 genetics as well as CYP2B6-mediated drug interactions.57 Reduced methadone metabolism was observed in
severe liver impairment, but in mild to moderate liver impairment the metabolism of methadone was near normal levels.47

PKs in adults

PKs in neonates

Studies in adults showed that methadone has relatively high
but variable bioavailability, with reported values ranging
from 41%–76% to 85%–95%.51 Reported average values of
Tmax are between 2.5 and 4.4 h.51 Methadone is highly lipophilic, with percent plasma protein bound greater than 90%
and a relatively large volume of peripheral compartment.
Methadone time-concentration can be modeled using a bi-
exponential function, with a rapid distribution phase and a
slow elimination phase.51 The estimated volume of distribution for methadone approximates 2.7 to 4.2 L/kg.52 Methadone
is metabolized to two inactive metabolites, 1,5-dimethyl-3,3
-diphenyl-2-ethylidene-pyrrolidine (EDDP) and 2-ethyl-5-m
ethyl-3,3-diphenylpyrroline.53 Although CYP3A4 was long
considered to be the major metabolizing enzyme of methadone, recent evidence has shown that CYP2B6, not CYP3A4,
is predominantly responsible for methadone metabolism in
humans.54 Reported clearance ranges from 4 to 11 L/h, and
correspondingly terminal half-life ranges from 19 to 43 h.52
Variability in the elimination half-life among individuals can

Ward et al.53 studied the population PK of intravenous methadone and its metabolites in neonates, infants, and children
by pooling PK observations from four studies (N = 56). A
3-compartment model was proposed with allometric scaling applied to PK parameters of racemic methadone, and
parameter estimates standardized to a 70 kg adult were 21.5
L/70 kg for central volume, 75.1/70 kg and 484 L/70 kg for
the 2 peripheral volumes, and 9.45 L/h/70 kg for clearance.
No maturation effect on clearance was noted, overall standardized parameter estimates in children and neonates were
close to those reported in adult studies.53 The effect of PMA
was only significant on the rapidly equilibrating peripheral
volume, and this relationship was described using a decreasing asymptotic exponential function. In this study, the differences in clearance in neonates and children/adolescents
could be explained sufficiently by allometry, and the authors
postulated that high CYP3A7 levels in fetal liver might be
contributing to clearance in neonates.53 However, as recent evidence has identified CYP2B6, not CYP3A4, as the
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major metabolizing enzyme of methadone, we can hereby
propose an alternative explanation. One study of human hepatic CYP2B6 developmental expression in pediatric liver
samples found that despite significant interindividual variability, CYP2B6 expression was detected in the majority
of the fetal and neonatal samples; additionally, the authors
observed only a two-fold increase in CYP2B6 expression
levels after the neonatal period.58 A more recent study found
that CYP2B6 activity occurred as early as the first day of
life, and the levels and activity increased through infancy
and they may approach adult values by 1 year.59 In agreement with their findings, the lack of maturation effect of age
on clearance in the PK analysis by Ward et al. could possibly
be explained by (1) sufficient ability in many neonates to
metabolize CYP2B6 substrates and/or (2) insufficiency of
the age effect in the context of large variability of CYP2B6
activity.
Population PK of methadone in neonates with NOWS receiving two dosing schemes orally were reported by Wiles
et al.60 based on observations from 20 patients (Table 1).
Large interindividual variability in methadone and metabolite concentrations was noted in the model-building process.60 A one-compartment model with first-order absorption
was used to fit the data, and allometric scaling on clearance
and volume terms was incorporated. Similar to the model by
Ward et al.,53 maturation factor based on PMA was explored
but did not improve the model fit, so it was excluded from
the model.60 Estimated standardized apparent clearance (8.94
L/h/70 kg) was similar to adult values, whereas the estimated
standardized apparent volume (177 L/70 kg) was at the low
end of adult values60; correspondingly half-life was calculated to be 14 h.
The study by van Donge et al.61 was the first clinical investigation on single dose PKs of oral methadone in preterm
neonates (Table 1). The authors developed a population PK
model of methadone using 121 methadone concentrations

F I G U R E 2 Comparative
pharmacokinetic (PK) parameters and
elimination of methadone in neonates/
infants and adults. *Apparent parameter
estimates from a population PK model
by Wiles et al.60 NE, not estimated; t1/2,
terminal half-life
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collected from 31 preterm neonates (GA between 26 and
36 weeks), and 2 enantiomers of methadone were modeled
separately using 1-compartment models with first-order absorption. In contrast to previous population PK models in
neonates where age descriptors were not included on clearance after allometric scaling was incorporated, in this study,
GA was incorporated on clearance and volume terms in a
power function and a linear function, respectively, whereas
allometric scaling was not incorporated on PK parameters.61
Apparent clearance of (R)-
methadone and (S)-
methadone
in preterm neonates was estimated to increase about 5 times
from 26 weeks to 36 weeks of GA (from 0.0997 to 0.5574 L/h
and from 0.0692 to 0.3708 L/h, respectively).61 This could
potentially be explained by the development of CYP2B6 activity in preterm neonates who may have lower metabolic capacity than term neonates, and/or the high correlation of GA
with body weight (r = 0.82) in this study as allometric scaling
was not incorporated.
More recently, McPhail et al.62 adapted a physiologically-
based pharmacokinetic (PBPK) model in adults to neonates
with NOWS using the same clinical data from Wiles et al.,60
aiming to further the understanding of the large PK variability observed. Similar to the population PK model by Wiles
et al.,60 this PBPK model reasonably predicted methadone
PK,62 but there remained significant unexplained PK variability. Findings from this PBPK model suggested that (1)
CYP2B6 is the major metabolizing enzyme of methadone,
and (2) CYP2B6 expression at birth is at adult levels, both of
which are consistent with assessment of clinical methadone
disposition and CYP2B6 ontogeny presented above.54,58,62
Overall, this study indicated that CYP enzyme activity and
protein binding could significantly affect methadone disposition, and therefore CYP2B6 polymorphisms could be a contributing factor to the observed interpatient PK variability.62
A summary of neonatal and adult PK parameters and
methadone elimination is presented in Figure 2.

1238

|

  

Buprenorphine
Pharmacology
Buprenorphine is a partial μ-opioid agonist approved for
treatment of opioid use disorder.63 It produces effects typical of μ-opioid agonists, including analgesia, euphoria, sedation, and respiratory suppression.64 However, in contrast to
full μ-opioid agonists, the effects of buprenorphine, including euphoria-
related subjective measures and respiratory
suppression, were found to plateau at high doses.65 Ceiling
effects on PDs of buprenorphine were found to translate
to a wider safety margin compared with full agonists.65
Although buprenorphine’s major metabolite, norbuprenorphine, has much less analgesic potency than buprenorphine,
the former may cause more respiratory depression than
buprenorphine.66

PKs in adults
Buprenorphine has very low oral bioavailability due to
extensive first-pass metabolism; however, adequate sublingual bioavailability makes sublingual dosing feasible.64 In adults, the bioavailability of sublingual solution
is estimated to range from 28% to 51%, and significant
interindividual variability has been noted.67,68 In terms of
sublingual exposure time, one study demonstrated similar
percent absorbed after holding the solution for 2.5 min or
10 min,69 but it is possible that even shorter hold times
could reduce the dose absorbed. In adults, Tmax is ~ 1 h
after sublingual dosing.67 Buprenorphine is highly lipophilic with extensive distribution. When administered intravenously, the volume of distribution of buprenorphine
is estimated to be between 188 and 335 L, which appears
to be larger when administered sublingually possibly due
to the reservoir effect of oral mucosa.64,67 Buprenorphine
is extensively metabolized by CYP3A4 to a N-dealkylated
metabolite, norbuprenorphine, and both are subsequently
metabolized to glucuronides.70 Buprenorphine is a high
extraction ratio drug with average plasma clearance in
healthy subjects ranging from 55.6 to 115.3 L/h following
intravenous administration.64 Reported values of elimination half-life are highly variable, with mean values from
individual studies ranging from 3 to 44 h following sublingual administration.64

PKs in neonates
Previous reports found that neonates had higher
buprenorphine-
to-
norbuprenorphine ratio than adults,
possibly due to immaturity of hepatic function of the
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neonates.64 Specifically, it was thought that CYP3A7, the
major fetal hepatic cytochrome P450 enzyme, was not able
to metabolize buprenorphine.64
Barrett et al.71 studied the PKs of buprenorphine in 12
premature neonates following intravenous infusion, and
reported that the average values of clearance, elimination
half-life, and volume of distribution using a 1-compartment
model were 0.23 L/h/kg, 20 h, and 6.2 L/kg, respectively.
The reported clearance value was significantly lower than
adult values, reflecting the immaturity of the metabolism
process in neonates. One limitation of this study is that the
buprenorphine concentrations were measured by a radioimmunoassay that could cross-
react with buprenorphine
72
glucuronide, whereas newer assays involving mass spectrometry used in more recent studies have much higher
specificity.
Ng et al.73 reported a two-compartment linear population PK model of sublingual buprenorphine based on
observations from 24 neonates with NOWS and 5 healthy
subjects (Table 1). After the effect of weight on PK parameters was accounted for by allometric scaling, the effect
of PNA on clearance was described by a combination of
two maturation models (a sigmoidal Emax model and an
exponential model), whereas the effect of PNA on peripheral volume was described by a sigmoidal Emax model.73
Typical values of apparent clearance and elimination half-
life for neonates weighing 2.9 kg and aged 5.4 days were
estimated to be 3.5 L/kg/h and 11 h.73 It was estimated that
at PNA of 0.5 days and 9.35 days, apparent clearance standardized to a 70 kg person would achieve 50% and 90% of
adult value, respectively.73 Based on the model estimated
apparent clearance and previously reported clearance in
preterm neonates following intravenous administration
(0.23 L/kg/h) by Barrett et al.,71 the bioavailability of the
sublingual formulation was estimated to be only 7%.73
The authors commented that this estimated bioavailability in neonates was much lower than reported adult values
(28%–51%), possibly due to different factors that affected
sublingual absorption and/or a larger fraction of dose
swallowed.73
The population PK model by Ng et al.73 was later
adapted to data from another clinical trial in a PK-PD analysis by Moore et al.74 The population PK model in this
analysis was based on 265 PK observations (buprenorphine
and norbuprenorphine) from 28 patients treated with sublingual buprenorphine.74 In the parent buprenorphine model-
building process, the model structure was based on the
prior Ng model, whereas some of the parameters were re-
estimated.74 After the parent model was fit, it was extended
to a parent-metabolite model, where the norbuprenorphine
PK was modeled by a one-compartment model, and allometric scaling was incorporated and a sigmoidal Emax maturation model was added to clearance of norbuprenorphine.74
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Standardized apparent clearance, central volume, and peripheral volume of buprenorphine were estimated to be
203 L/h/70 kg, 142 L/70 kg, and 6350 L/70 kg, which were
within 30%–40% of the previously estimated values in the
Ng model.74
Mizuno et al.75 also reported a population PK-PD analysis in patients with NOWS treated with sublingual buprenorphine (52 buprenorphine PK observations from 19 neonates).
In contrast to the previous reports, a one-compartment model
with first-order absorption was used to describe the PK data,
and no age descriptors were included in the PK model after
incorporation of allometric scaling.75 The estimate of standardized clearance (32.6 L/h/70 kg) was also lower than
those from previous studies.75 Such differences from previous
models were likely resulted from some important limitations
of the PK sampling in this study, where a limited number of
PK samples were all taken around the second dose of buprenorphine. As a result of this limited PK sampling time
window, insufficient information could be derived regarding
terminal phase of buprenorphine PKs and the maturation of
buprenorphine clearance over the length of typical treatment
duration.
More recently, Kovar et al.76 developed a PBPK model in
preterm neonates from scaling an adult model of buprenorphine and norbuprenorphine, by accounting for age-related
changes (e.g., size, protein binding, maturation of elimination
processes, and tissue compartment composition). Evaluation
of this model in preterm neonates was performed using clinical PK data reported by Barrett et al.,71 and applicability of
such a scaling approach was demonstrated by the ability of
the model to predict 75% of individual AUC within a twofold
range.76
A summary of neonatal and adult PK parameters and buprenorphine elimination is presented in Figure 3.

F I G U R E 3 Comparative
pharmacokinetic parameters and elimination
of buprenorphine in neonates/infants and
adults. *Sublingual dosing. #Estimated in
premature neonates.71 ^Relative ratio of
buprenorphine to norbuprenorphine. NE, not
estimated t1/2, terminal half-life

|

1239

Clonidine
Pharmacology
Clonidine is a centrally acting antihypertensive agent, and
it is also clinically used in pediatric anesthesia as premedication or an analgesic.77 It is an imidazole compound that
acts as a selective partial agonist at α2-adrenergic receptors, and its cardiovascular effects are thought to be mediated through stimulation of α2-inhibitory neurons in the
medulla oblongata that leads to reduction in noradrenergic neurotransmission.78 Specifically, clonidine stimulates
presynaptic α2-adrenergic receptors and decreases norepinephrine release and consequently peripheral sympathetic
output to the heart and vasculature.78 Additionally, it exerts
its sedative effect in the locus coeruleus where it inhibits the spontaneous firing of the nucleus, leading to CNS
suppression.77

PKs in adults
Clonidine is highly bioavailable and readily absorbed; reported mean bioavailability values are from 75% to 90%,
and Tmax occurs between 1.5 and 2.5 h after oral administration.79,80 Clonidine is also commercially available as
transdermal patches that are designed to deliver the drug
at an approximately constant rate for 7 days, and the absolute bioavailability of transdermal patches is ~60%.81,82
In a healthy volunteer study with transdermal patches,
steady-state concentrations were achieved by the end of
the second day.81,82 Clonidine is highly lipophilic, and
it can readily penetrate the blood-brain barrier and enter
extravascular space.83 Its disposition has been described
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with 2-compartment models, and the reported volume of
distribution ranges from 2 to 5 L/kg.79,80 Entero-hepatic
circulation was reported by Arndts et al., who observed
a resurgence of plasma concentrations 15–20 min after a
meal.84 About 40%–60% of a clonidine dose is excreted
unchanged in the urine while the remainder is metabolized
to inactive metabolites primarily by CYP2D6.83 The renal
clearance is estimated to be ~ 7.6 L/h (127 ml/min) with
significant variability, which exceeds the GFR in some
subjects.80 Dose-dependent kinetics have been observed in
some studies, where one study reported that the systemic
clearance decreased from 24 to 13 L/h (5.8 to 3 ml/min/kg)
when the intravenous dose administered increased from 75
to 275 μg.85 Another study by the same group reported that
as the intravenous dose increased from 1.27 to 3.36 μg/kg,
clearance estimates decreased from 16.8 to 10.9 L/h (4–
2.6 mL/min/kg).79 Overall, the reported elimination half-
life of clonidine ranges from 6 to 13 h.79,80 The elimination
half-life after removal of the transdermal patch is relatively
longer, ranging from 14 to 26 h.81

PKs in neonates
Age may affect the clearance of clonidine by impacting the
development of GFR and CYP2D6 mediated metabolism.86
CYP2D6 expression and activity develop rapidly in the first
week of life, and age did not significantly affect CYP2D6
expression or activity levels among postnatal liver samples
from subjects greater than 7 days of age.87 In contract, standardized GFR rises steadily after an initial rapid increase,
reaching adult values at 8–12 months of age.88
Reported oral and transdermal dosing in critically ill infants and children ranged from 2–15 µg/kg/day divided every
6–8 h and from 2.3 to 20 µg/kg/day, respectively, but the PK
data of oral or transdermal clonidine in this patient population is limited.89 One PK study of oral clonidine in children
(3–10 years) reported a Tmax of ~ 1 h and bioavailability of
55.4%.90 Another PK study of transdermal clonidine in critically ill children (0.3–11 years) concluded that rate and extent of absorption was more predictable with whole patches
compared with cut patches.91
Using data from published PK studies in infants and children who received intravenous, rectal, or epidural clonidine
(380 observations from 72 subjects, aged 0–14 years), Potts
et al.83 reported a population PK model incorporating allometric scaling of PK parameters and asymptotic exponential
maturation of clearance based on PNA. A two-compartment
model was used for data fitting, and the normalized parameter estimates for 70-kg adults were 14.6 L/h for clearance,
62.5 L for central volume, and 119 L for peripheral volume.
These standardized values are close to reported values in
adult studies. Clearance at birth standardized for weight was
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estimated to be 3.8 L/h/70 kg, and maturation half-life was
estimated to be 25.7 weeks.83 The reduced clearance in the
pediatric population was attributed to immaturity of elimination pathways. The authors concluded that this maturation
half-life reported from their model was consistent with the
development timeline of the renal system.83
Xie et al.92 reported a population PK model based on 102
observations from 36 neonates with NOWS treated with oral
clonidine (Table 1). A one-compartment model was used. The
apparent clearance was modeled with an allometric power
model combined with a sigmoid maturation model based on
PNA, and the apparent volume was modeled with an allometric power model. For the final parameter estimates, the
absorption rate constant was 0.533/h, the apparent clearance,
and the apparent volume standardized to 70 kg were 15.2 L/h
and 391 L, respectively.92 Based on this model, typical values
of apparent clearance, apparent volume, and half-life for neonates weighing 2.9 kg and aged 7.5 days were estimated to
be 0.27 L/kg/h, 5.6 L/kg, and 14.2 h. Although the standardized value of clearance was close to previous reported values,
the maturation half-life was estimated to be 4.1 days, and the
estimated time to reach 70% weight-adjusted adult value of
clearance was 1 month, compared with 9 months according
to the findings by Potts et al.83,92 It was postulated that this
discrepancy is due to different age distributions in the two
studies, as in the study by Potts et al., only a small number of
subjects were neonates.83
A summary of neonatal and adult PK parameters and
clonidine elimination is presented in Figure 4.

Phenobarbital
Pharmacology
Phenobarbital is a conventional anti-epileptic drug that is
also used as an adjunctive treatment in NOWS. Phenobarbital
causes CNS depression through its action on GABAA receptors, and it also produces dose-
dependent respiratory
depressant effect.93 Through changing neuronal membrane
conductance, especially of sodium and calcium, phenobarbital produces a wide range of complex neurochemical and
neurophysiological effects.94

PKs in adults
Phenobarbital is slowly absorbed but is highly bioavailable
(~90%) after dosing.95 Reported volume of distribution in
adults is ~0.6 to 0.7 L/kg.95,96 Phenobarbital binds primarily to albumin in the plasma, and the degree of protein binding is relatively low (~50%).95 It is metabolized primarily
by CYP2C9, and by CYP2C19 and CYP2E1 to a lesser
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F I G U R E 4 Comparative
pharmacokinetic (PK) parameters and
elimination of clonidine in neonates/infants
and adults. *Dose-dependent decrease in
clearance.85#Apparent parameter estimates
from a population PK model by Xie et al.,
half-life estimated in a typical neonate.92
GFR, glomerular filtration rate; NE, not
estimated; t1/2, terminal half-life

F I G U R E 5 Comparative
pharmacokinetic parameters and elimination
of phenobarbital in neonates/infants and
adults. *Bioavailability was reported to be
lower than in adults.99#Half-life estimates
reported for term and preterm neonates.94
t1/2, terminal half-life

extent.95,97 About 20%–40% of the drug is excreted through
the kidney, and renal excretion is dependent on urine flow
and pH.95,97 Clearance of phenobarbital can be affected
by age, disease states, and certain concomitant drugs.95 In
adults, phenobarbital clearance is about 0.004–0.006 L/h/kg,
with a half-life of ranging from 70 to 140 h.94,95,97,98

PKs in neonates
Although very high bioavailability is observed in adults, one
study reported the bioavailability of oral phenobarbital in
neonates and young infants to be ~48.9%.99 Plasma binding
in neonates is lower than in infants/children and adults, and
conversely neonates have slightly higher volumes of distribution (~0.9–1 L/kg) than the latter.95,100 In neonates, clearance is estimated to be 0.005 L/h/kg.95,99 One study reported
that whereas clearance was consistent in neonates who maintained on therapy for 1–4 weeks, the half-life of phenobarbital decreased from 115 h at 1 week to 67 h at 4 weeks.100

Due to its prolonged half-life, the suggested dosing regimen
of phenobarbital in neonates consists of a loading dose of 15–
25 mg/kg, followed by an oral maintenance dose of 2–4 mg/
kg/day.95 Unlike the other therapeutic agents discussed in
detail in this review, therapeutic drug monitoring (TDM)
is commonly used in neonates for phenobarbital, due to its
significant PK variability and narrow target range.98 Its suggested reference range in plasma is 10–40 mg/L.98
Although no population PK analysis has specifically been
conducted for neonates with NOWS, a number of population PK studies have been conducted in pediatric and adult
patients with other disease indications (e.g., epilepsy). A
review of these studies is available elsewhere.97 Briefly, a
one-compartment structure was used in all studies included
(likely due to sparse sampling), and three most commonly
identified predictors of clearance were weight, age, and concomitant anti-epileptic drugs (phenytoin, carbamazepine, or
valproic acid).97
A summary of neonatal and adult PK parameters and phenobarbital elimination is presented in Figure 5.
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CU R R EN T D OS ING A N D
PH A R M ACO ME T R IC S-D R IV E N
DO S ING O P TIMIZ AT IO N IN NOWS
As only recently have the population PK-PD of pharmacologic agents been investigated in NOWS, dosing regimens
have been mostly empirical.101 Reported initial starting doses
of morphine are highly variable; the recommended dosing
regimen in the 2012 update of AAP Guidelines lists an initial
dose of 0.04 mg/kg every 3–4 h, dosing escalation in increments of 0.04 mg/kg, and a maximum dose of 0.2 mg/kg.3
Weaning usually takes place after symptomatic stabilization
for 48 h, and daily dose can be decreased by 10% to about
0.15 mg/kg/day, although there is a lack of consensus on specific dosing regimens.102 For methadone, the AAP statement
recommends a starting dose of 0.05–0.1 mg/kg every 6 h and
dose escalation increments of 0.05 mg/kg per dose.3 Similar
to morphine, the dose can be decreased after stabilization for
24–48 h, and can be discontinued when the patient is stable at
0.01 mg/kg daily.102 For clonidine, the recommended starting
dose is 0.5–1 μg/kg every 3–6 h, and the maximum dose is
1 μg/kg every 3 h.3 Clinical experience with buprenorphine is
relatively limited compared with morphine and methadone,
and specific dosing schemes of buprenorphine were reported
in randomized trials or retrospective cohort studies.103–106 In
the initial randomized trial by Kraft et al., the dosing range
of sublingual buprenorphine was 13.2–39.0 μg/kg/day in 3
divided doses; the uptitration rate was 20%, and weaning occurred at a rate of 10% until the dose was at or near the initial
dose.105 In subsequent trials by the same group, the dosing
range and uptitration rate were increased to 15.9–60 μg/kg/
day in 3 divided doses and 25%, respectively, due to observations of frequent use of maximum dose, low plasma levels,
and lack of opioid toxicity in the initial study.103,104 As the
PKs and PDs of these agents become more and more well-
characterized with ongoing clinical studies, pharmacometric
analyses should be used to determine the optimal dosing regimen to achieve early control of withdrawal symptoms and/or
optimize the weaning scheme.
In adults, the primary goal of maintenance treatment for
opioid dependence is to adequately suppress withdrawal signs
and symptoms. Previous studies with methadone or buprenorphine have shown that withdrawal severity had a positive
relationship with opioid receptor availability and a negative
relationship with plasma opioid concentrations.107–110 PK-PD
modeling has been conducted for buprenorphine and methadone using hyperbolic Emax and sigmoid Emax models to
describe the relationship between opioid concentrations and
opioid receptor occupancy or withdrawal severity, respectively.107–109,111 In order to minimize interdosing withdrawal,
one can use these modeling results to select doses that can
achieve concentrations that exceed predetermined opioid receptor occupancy associated with suppression of withdrawal.
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For example, Greenwald et al.63 demonstrated that 50%–60%
of opioid receptor occupancy by buprenorphine is needed to
achieve adequate withdrawal suppression, whereas 70% occupancy is associated with additional clinical benefit. Based
on this finding, Nasser et al.107 used a sigmoid Emax model to
predict that a buprenorphine plasma concentration of 2 ng/ml
was needed to obtain 70% opioid receptor occupancy.
Regarding the selection of the optimal dosing regimen
in NOWS, the natural course of withdrawal severity in these
neonates increases after birth and decreases after some time
interval. Additionally, as the end goal is to achieve the gradual abstinence from opioids instead of an opioid maintenance
therapy, it is therefore not appropriate to target a consistent
level of opioid concentration and/or receptor occupancy in
NOWS throughout the therapy. Instead, it is much more reasonable and straightforward to focus the dose selection effort
on optimization of early dose exposure (i.e., the uptitration
phase).
Xie et al.92 conducted a simulation of steady-state clonidine concentrations following 1, 1.5, or 2 µg/kg dosed every
4 h and used 0.8 and 1 ng/ml as target minimum clonidine
concentrations. However, no PK-PD assessment was done to
link these target concentrations to PD end points in NOWS.
Based on the simulation results, the authors proposed that
1.5 µg/kg every 4 h would be needed starting the second
week of life to achieve the target concentrations (Table 2).92
However, this simulation analysis appeared to have oversimplified the dosing scenario in NOWS and failed to recognize
that the clonidine concentration should be a moving target
depending on the uptitration or the weaning phase. For example, infants who achieve stabilization of withdrawal scores
in their first week of life will likely be in the weaning stage
in the second week. Therefore, it may not be clinically appropriate to propose a dose based on the postnatal age alone;
instead, the phases of treatment also need to be taken into
consideration.
In a methadone population PK analysis, Wiles et al.60
used the modeling results to optimize the methadone dosing regimen used at their institutions. Their original methadone dosing strategy consisted of two dosing schemes
(Table 2). Briefly, all patients were started on 0.05 mg/kg
of methadone every 6 h. If the patients responded with decreased withdrawal scores over 24 h, they were continued
on the remaining steps of dosing scheme 1; otherwise they
were subsequently treated according to dosing scheme 2.60
The authors first identified AUC values observed after the
first 48 h (for dosing scheme 1) and 72 h (for dosing scheme
2) when the subjects achieved stabilization of withdrawal
scores, respectively.60 Then the authors simulated 2 new dosing schemes that could achieve these AUC targets at 24 h and
48 h, respectively.60 Based on their simulation results, it was
suggested that most patients could be started on 0.1 mg/kg
every 6 h to achieve earlier control of symptoms compared to
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References

Agent

Dosing scheme before
optimization

Proposed dosing scheme
after optimization

Xie et al.92

Clonidine

1 µg/kg q4 h

1.5 µg/kg q4 h starting the
second week of life

Wiles et al.60

Methadone

Dosing scheme 1:
0.05 mg/kg q6 h × 4
0.04 mg/kg q6 h × 4
0.03 mg/kg q6 h × 4
0.02 mg/kg q6 h × 4
0.02 mg/kg q8 h × 3
0.02 mg/kg q12 h × 4
0.01 mg/kg q12 h × 4
0.01 mg/kg q24 h × 2

Dosing scheme 1:
0.1 mg/kg q6 h × 4
0.075 mg/kg q12 h × 2
0.05 mg/kg q12 h × 2
0.04 mg/kg q12 h × 2
0.03 mg/kg q12 h × 2
0.02 mg/kg q12 h × 2
0.01 mg/kg q12 h × 2
0.01 mg/kg q24 h × 1

Dosing scheme 2 (for
patients’ refractory to
step 1 of scheme 1):
0.05 mg/kg q6 h × 4
0.1 mg/kg q6 h × 4
0.075 mg/kg q6 h × 4
0.05 mg/kg q6 h × 4
0.04 mg/kg q6 h × 4
0.03 mg/kg q6 h × 4
0.02 mg/kg q6 h × 4
0.02 mg/kg q8 h × 3
0.02 mg/kg q12 h × 4
0.01 mg/kg q12 h × 4
0.01 mg/kg q24 h × 2

Dosing scheme 2:
0.1 mg/kg q4 h × 6
0.1 mg/kg q8 h × 3
0.1 mg/kg q12 h × 2
0.075 mg/kg q12 h × 2
0.05 mg/kg q12 h × 2
0.04 mg/kg q12 h × 2
0.03 mg/kg q12 h × 2
0.02 mg/kg q12 h × 2
0.01 mg/kg q12 h × 2
0.01 mg/kg q24 h × 1

Initial dose: 5.3 µg/kg q8 h

Initial dose: 15 µg/kg q8 h

Moore et al.74

Buprenorphine

when original dosing schemes 1 and 2 were used (Table 2).60
The optimized methadone dosing protocol was tested prospectively in a prepost cohort study by Hall et al.112 In this
study, 360 infants in total were included in the analysis (267
in the standard protocol and 93 in the revised protocol). The
authors reported that compared with infants treated with the
standard protocol, those treated with the revised dosing protocol had significantly shorter treatment duration (13.1 vs.
16.4 days) and length of stay (18.3 vs. 21.7 days), whereas
total methadone dosage and use of adjunctive therapy did not
differ in the two groups. This study was an elegant example
that demonstrated the potential of using knowledge of clinical pharmacology to improve existing treatment protocols.
Similarly, van Donge et al.61 built a population PK model of
methadone in preterm neonates with NOWS, and performed
simulations to design dosing regimens needed to achieve the
AUC target reported by Wiles et al.60
The study by Moore et al.74 provided further support for
the dosing optimization effort guided by target exposure in
the early phase of treatment. The authors reported that neonates with similar severity of NOWS were generally able to
achieve stabilization of their symptoms (defined as when the
average of previous 12 scores was <8 with the MOTHER
NAS Scale) when they had similar AUC exposure to buprenorphine, and a negative relationship between the average

plasma concentrations (Cave) and time to stabilization was
observed.74 Based on these observations, Moore et al.74 performed a survival regression dividing the infants into quartiles of Cave with NOWS severity added as a covariate. As
0.8 ng/ml was the Cave in the highest concentration quartile
from the survival analysis, it was treated as the concentration target and used to derive a more effective initial dose of
15 µg/kg every 8 h (Table 2).74
Studies by Wiles et al.60 and Moore et al.74 provide strong
support for optimizing dosing in the early phase of treatment
based on targeted exposure, with the goal of achieving early
symptom stabilization to shorten the length of treatment.
Following the construction and evaluation of population PK
models, the basic principle was to first establish target exposure metrics (e.g., AUC and Cave) that were associated with
early symptom stabilization, and subsequently simulate dosing regimen to achieve the target exposure.
It is understandably more challenging to optimize dosing
in the weaning phase as the natural disease remission must
be taken into consideration, in addition to modeling available
PK and PD data in treated patients. Weaning of the pharmacologic agent is usually done incrementally over time,
which was one of the reasons that the length of hospital stay
is prolonged in infants with NOWS.3,9 However, there have
been no clinical studies addressing whether long medication
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weans are necessary or effective.113 Moore et al.74 proposed
that their population PK-PD model of buprenorphine may
serve as a starting point for a rational approach to weaning
that allows changing of dosing frequency. Similarly, Mizuno
et al.75 developed a buprenorphine population PK-PD model
in NOWS. Both studies used differential equations to model
the disease progression using withdrawal scores as the PD
marker, and included the component of natural disease remission in the model building process.74,75 Half-maximal inhibitory concentration (IC50) estimates obtained from these two
studies (0.509 ng/ml and 0.766 ng/ml, respectively) were reasonably close to the previously reported IC50 value in adults
treated for opioid dependence (0.67 ng/ml).74,75,107 However,
substantial unexplained interpatient variability remained in
these PK-PD models, which undermines their predictive performance and their ability to facilitate model-informed dosing
optimization. One important reason is that withdrawal scores
are generally highly variable because of the subjective nature
of the scoring tools, which are also subjective to changes due
to intentional nonpharmacologic treatment as well as unintentional environmental cues. On top of the limitations of
current scoring systems, disease severity in NOWS is known
to be heterogenous and can be affected by a variety of clinical factors (e.g., types of utero opioid exposure, concomitant
exposure to other substances, and gestational age) as well as
genetic factors.114,115 For these reasons, we could foresee limitations of using PD modeling based on withdrawal scores to
guide dosing frequency in the weaning phase. On the other
hand, there have been an increasing number of clinical studies aiming to simplify weaning protocols empirically. For example, two published quality improvement projects sought
to optimize nonpharmacologic therapy and reduce morphine
dosing to allow faster weaning and as-needed administration,
and the authors reported significant decrease in morphine
doses administered and length of hospital stay compared with
the traditional approach.116,117 Additionally, in a recent randomized clinical trial comparing the use of methadone versus morphine in 116 infants with NOWS, the authors found
that allowing for more rapid weaning of the drug (from every
24–48 h to every 12 h) minimized the occurrence of adverse
events.16 Together, these clinical findings may indicate the
need to shorten the lengthy weaning in clinical protocols for
both efficiency and safety reasons.

FU TU R E P E R S P E C T IV E S
PK studies in neonates are, in general, very challenging to
conduct and therefore population PK modeling has been a
very powerful tool in analyzing pediatric PK data given the
commonly observed data sparsity and imbalance. Using population PK models, significant patient-specific factors impacting PK can be taken into consideration when performing
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dose regimen optimization aiming to achieve targeted exposure. In the case of phenobarbital, for which TDM is routinely
performed, population PK with Bayesian forecasting is an
emerging concept to provide for effective dose individualization. Specifically, significant patient-specific factors identified in the population PK model can be utilized to first derive
individual PK estimates for determining the initial dosing
regimen; these individual estimates can later be improved by
incorporating individual TDM measurements and allow for
dose adjustment based on Bayesian forecasting.118 This approach not only can result in more efficient individualized
dosing, but also can provide flexibility in clinical sampling
for TDM (e.g., non-steady-state concentrations).97
When applying population PK models, one needs to keep
in mind that the modeling results often need to be interpreted
within the context of their specific study population. For example, two published population PK models of clonidine in
pediatric patients incorporating PNA on weight-standardized
clearance yielded different prediction of clearance maturation trajectory, likely due to difference in age composition of
the studied population.83,92 Therefore, external evaluation of
these models in the target population is needed when applying these models. There is also a need for more high-quality
PK studies in neonates to bolster existing data and better
guide evidence-based dosing in NOWS. Some trial design elements need to be taken into consideration before conducting
PK studies in neonates, including sufficient sample size and
reasonable selection of sampling schemes that would allow
adequate estimation of PK parameters; it is therefore important to assess available PK information in pediatric and adult
patients and knowledge about ontogeny of relevant organ and
enzyme systems to better inform the trial design.119 In addition, in neonate trials, patient burden and clinical feasibility also need to be considered when choosing the sampling
scheme, and therefore opportunistic sampling (e.g., timing
research samples with clinically indicated blood draws)
and scavenged sampling using surplus blood drawn during
routine care may be considered to improve study feasibility
and reduce patient discomfort.120 Additionally, dried matrix
spot sampling and micro-volume assays can be considered
as ways to reduce the blood volume needed for sampling.121
In the past decade, there has been a growing interest in
the use of PBPK modeling. Compared with the empirical
approach via population PK modeling, the mechanistic nature of PBPK modeling could facilitate the understanding
of physiological mechanisms governing drug disposition.122
Given the scarcity of pediatric PK data, PBPK modeling also
has the advantage of leveraging both preclinical and adult
data.123 In PBPK models, drug-specific parameters are generally separate from system-specific parameters, and therefore
they could be translated to a population with a different physiology by updating the system-specific parameters for the
target population, such as the neonates.122 The workflow for

  

PHARMACOLOGY OF NOWS TREATMENTS

developing a pediatric PBPK model starts from development
and verification of an adult PBPK model, followed by development and evaluation of a pediatric model123; this workflow
was implemented in two example studies with methadone and
buprenorphine mentioned earlier in the text.62,76 The most
important prerequisite for reliable translation to pediatrics is
knowledge of drug-specific ADME processes in adults and
ontogeny of such processes122; therefore, lack of qualified
systems data and existing knowledge gap in the rapid physiological changes and maturation of organs/tissues related to
drug disposition in neonates is expected to pose challenges to
developing robust PBPK models in pediatrics.119,124
Compared with PKs in pediatrics, there is in general limited information on how developmental changes and their
interaction with disease impact PD, and therefore quantifying drug effect in pediatric patients is considered the biggest
obstacle.125 This is particularly true in the case of NOWS,
where significant disease heterogeneity and the lack of reliable disease measures could potentially hinder the predictive performance of PK-PD models. In pediatric trials, it is
recommended to use functional biomarkers with sufficient
accuracy and precision, and adequate sensitivity to distinguish longitudinal changes in disease progression from drug
effect.125 Therefore, in addition to the ongoing effort on comparing the efficacy of different therapeutic agents/treatment
modalities, more research focus should also be placed on optimizing withdrawal scoring systems as well as identifying
objective measurements of disease severity in NOWS.
Regardless of the specific modeling approaches, safety
profiles should be considered when applying findings from
these modeling efforts. Although adverse events are uncommon with commonly used therapeutic agents in NOWS,126 it
is recommended to test higher initial dosing in an inpatient
setting and avoid implementing new protocols in an outpatient setting until more safety evidence becomes available.60

CO NC LU S IO N S
In this paper, we summarize the management of NOWS, clinical pharmacology for primary treatment agents, and review
available pharmacokinetic studies in NOWS. Pharmacologic
treatment strategies in NOWS have been mostly empirical,
and heterogeneity in reported dosing regimens makes it difficult to extrapolate some study results to broader patient
populations. As the population PK of pharmacologic agents
in NOWS become more well-defined, PK-PD modeling and
simulation is becoming an increasingly powerful tool that informs the optimal dosing regimen design.101 In most population PK studies, large interindividual variabilities have been
observed in model parameters, even after accounting for the
effects of weight and/or age. This is likely due to the presence
of other patient-specific factors that may affect the disposition
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and action of pharmacologic agents. For instance, genetic associations with disease severity and treatment outcomes have
been increasingly reported in recent years, which have been
reviewed elsewhere.127–129 As knowledge of patient-specific
factors affecting treatment outcomes continues to accumulate, it is foreseeable that future modeling efforts will continue to improve by incorporating these factors, allowing for
the personalized selection of treatment agents and strategies.
The ultimate goal would be to establish optimized treatment
protocols that allow the selection of evidence-based treatment strategies built on patient-specific factors.
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